Do ESR1-related mutations generate neoantigens in hormone-receptor-positive HER2-negative metastatic breast cancer?

被引：0
|
作者：
Lopez, M. [1 ]
Spehner, L. [1 ]
Ramseyer, M. [2 ]
Bouard, A. [2 ]
Dobi, E. [1 ]
Curtit, E. [1 ]
Borg, C. [1 ]
Mansi, L. [1 ]
机构：
[1] Hop Jean Minjoz, CHRU Besancon, Team Therapeut Immunomol Canc, Besancon, France
[2] Doubs, UMR1098, Besancon, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.653
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
477P
引用
收藏
页码：S382 / S382
页数：1
相关论文
共 50 条
  • [31] Clinical Importance of estrogen reactivity in Hormone Receptor Positive HER2-Negative Breast Cancer
    Takeshita, Takashi
    Iwase, Hirotaka
    Takabe, Kazuaki
    CANCER SCIENCE, 2023, 114 : 597 - 597
  • [32] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
    Garrigos, Laia
    Camacho, Daniela
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    Antonarelli, Gabriele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (10) : 949 - 958
  • [33] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Lopez-Tarruella, Sara
    Jerez, Yolanda
    Marquez-Rodas, Ivan
    Echavarria, Isabel
    Martin, Miguel
    FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
  • [34] Adjuvant chemotherapy in hormone-receptor positive HER2-negative early breast cancer
    Lopez, M.
    Di Lauro, L.
    Viola, G.
    Foggi, P.
    Conti, F.
    Corsetti, S.
    Sergi, D.
    Botti, C.
    Di Filippo, F.
    Vici, P.
    CLINICA TERAPEUTICA, 2009, 160 (06): : 481 - 488
  • [35] New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
    Brett, Jamie O.
    Mayer, Erica L.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (06) : 594 - 610
  • [36] Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy
    Lubna N. Chaudhary
    Julie M. Jorns
    Yunguang Sun
    Yee Chung Cheng
    Sailaja Kamaraju
    John Burfeind
    Mary Beth Gonyo
    Amanda L. Kong
    Caitlin Patten
    Tina Yen
    Chandler S. Cortina
    Ebony Carson
    Nedra Johnson
    Carmen Bergom
    Shirng-Wern Tsaih
    Anjishnu Banerjee
    Yu Wang
    Inna Chervoneva
    Elizabeth Weil
    Christopher R. Chitambar
    Hallgeir Rui
    Breast Cancer Research and Treatment, 2023, 201 : 387 - 396
  • [37] PATTERNS OF CLINICAL MANAGEMENT AND RESOURCE UTILIZATION FOR POSTMENOPAUSAL HORMONE-RECEPTOR-POSITIVE HER2-NEGATIVE (HR+HER2-) ADVANCED BREAST CANCER (ABC) IN EUROPE
    Jerusalem, G.
    Marinsek, N.
    Ricci, J.
    Etchberger, J.
    Degun, R.
    Benelli, G.
    Saletan, S.
    Andre, F.
    ANNALS OF ONCOLOGY, 2012, 23 : 122 - 122
  • [38] Activating HER2 missense mutations in HER2-negative metastatic breast cancer
    Shah, Mirat
    Ensminger, Jennifer
    Wang, Chenguang
    Ali, Siraj
    Chung, Jon
    Lauring, Josh
    Park, Ben Ho
    Stearns, Vered
    CANCER RESEARCH, 2020, 80 (04)
  • [39] New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer
    Jamie O. Brett
    Erica L. Mayer
    Current Treatment Options in Oncology, 2023, 24 : 594 - 610
  • [40] Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
    Noguchi, Shinzaburo
    Masuda, Norikazu
    Iwata, Hiroji
    Mukai, Hirofumi
    Horiguchi, Jun
    Puttawibul, Puttisak
    Srimuninnimit, Vichien
    Tokuda, Yutaka
    Kuroi, Katsumasa
    Iwase, Hirotaka
    Inaji, Hideo
    Ohsumi, Shozo
    Noh, Woo-Chul
    Nakayama, Takahiro
    Ohno, Shinji
    Rai, Yoshiaki
    Park, Byeong-Woo
    Panneerselvam, Ashok
    El-Hashimy, Mona
    Taran, Tetiana
    Sahmoud, Tarek
    Ito, Yoshinori
    BREAST CANCER, 2014, 21 (06) : 703 - 714
12345